Atrion (NASDAQ:ATRI) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Atrion (NASDAQ:ATRI) in a research report sent to investors on Monday morning. The firm issued a sell rating on the medical instruments supplier’s stock.

Atrion Stock Performance

ATRI opened at $454.47 on Monday. The company has a market cap of $799.87 million, a PE ratio of 42.71 and a beta of 0.68. The stock has a 50-day moving average of $448.45 and a 200-day moving average of $404.74. Atrion has a 52-week low of $274.98 and a 52-week high of $593.00.

Atrion (NASDAQ:ATRI) last released its quarterly earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter. The company had revenue of $47.33 million during the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%.

Atrion Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Friday, June 14th were paid a dividend of $2.20 per share. The ex-dividend date was Friday, June 14th. This represents a $8.80 annualized dividend and a dividend yield of 1.94%. Atrion’s dividend payout ratio (DPR) is presently 82.71%.

Institutional Trading of Atrion

Large investors have recently made changes to their positions in the stock. Penn Mutual Asset Management LLC acquired a new position in shares of Atrion during the 4th quarter worth about $1,949,000. Public Employees Retirement System of Ohio acquired a new position in shares of Atrion during the 1st quarter worth about $2,299,000. Citizens Financial Group Inc. RI acquired a new position in shares of Atrion during the 4th quarter worth about $1,114,000. Boston Trust Walden Corp lifted its position in shares of Atrion by 4.8% during the 4th quarter. Boston Trust Walden Corp now owns 35,091 shares of the medical instruments supplier’s stock worth $13,292,000 after purchasing an additional 1,609 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Atrion during the 1st quarter worth about $421,000. Institutional investors own 66.19% of the company’s stock.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.